ReviewPharmaceutical nanotechnology2026
Nanoparticle Carriers for Drug Delivery: An Updated Review.
Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endothelial metabolic zonation in the vascular network: a spatiotemporal blueprint for angiogenesis.American journal of physiology. Heart and circulatory physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug was initially administrated relying on pills, eye drops, ointments, and intravenous solutions. In the last decades, several novel technologies have emerged to overcome significant challenges including poor solubility, drug aggregation, low bioavailability, limited biodistribution, poor absorption in the body, lack of selectivity, or to minimize the adverse effects of therapeutic drugs. Drug delivery systems (DDS) can be designed to the technologies that carry drugs into or throughout the body of humans or animals to enhance therapeutic efficacy. DDS can also be considered for in vivo delivery, particularly for their use in peptide and protein therapeutics. Continued research may show the trends and perspectives of how drugs are delivered. In addition, this article includes comprehensive information regarding the trends and perspectives in DDS technologies.
Indexed as
Identifiers
39757617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.